

# Olivier Rohr

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1912754/publications.pdf>

Version: 2024-02-01

36  
papers

2,386  
citations

331259

21  
h-index

344852

36  
g-index

38  
all docs

38  
docs citations

38  
times ranked

2682  
citing authors

#	ARTICLE	IF	CITATIONS
1	Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO Journal, 2007, 26, 412-423.	3.5	318
2	Microglial Cells: The Main HIV-1 Reservoir in the Brain. Frontiers in Cellular and Infection Microbiology, 2019, 9, 362.	1.8	237
3	An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatins-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression. PLoS Pathogens, 2015, 11, e1005063.	2.1	229
4	Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology, 2010, 7, 32.	0.9	159
5	Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. Journal of Leukocyte Biology, 2003, 74, 736-749.	1.5	125
6	Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs. Frontiers in Microbiology, 2019, 10, 3060.	1.5	114
7	Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro. Viruses, 2021, 13, 354.	1.5	113
8	p21WAF1 gene promoter is epigenetically silenced by CTIP2 and SUV39H1. Oncogene, 2009, 28, 3380-3389.	2.6	108
9	COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells. Nucleic Acids Research, 2005, 33, 2318-2331.	6.5	98
10	Targeting the Brain Reservoirs: Toward an HIV Cure. Frontiers in Immunology, 2016, 7, 397.	2.2	92
11	CTIP2 is a negative regulator of P-TEFb. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12655-12660.	3.3	86
12	Sequential treatment with 5-azacytidine and deacetylase inhibitors reactivates HIV-1. EMBO Molecular Medicine, 2016, 8, 117-138.	3.3	73
13	Recruitment of Tat to Heterochromatin Protein HP1 via Interaction with CTIP2 Inhibits Human Immunodeficiency Virus Type 1 Replication in Microglial Cells. Journal of Virology, 2003, 77, 5415-5427.	1.5	68
14	LSD1 cooperates with CTIP2 to promote HIV-1 transcriptional silencing. Nucleic Acids Research, 2012, 40, 1904-1915.	6.5	65
15	HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes. Journal of Leukocyte Biology, 2009, 87, 575-588.	1.5	56
16	Functional Interactions between C/EBP, Sp1, and COUP-TF Regulate Human Immunodeficiency Virus Type 1 Gene Transcription in Human Brain Cells. Journal of Virology, 2000, 74, 65-73.	1.5	55
17	Achieving a cure for HIV infection: do we have reasons to be optimistic?. Journal of Antimicrobial Chemotherapy, 2012, 67, 1063-1074.	1.3	49
18	HMGA1 recruits CTIP2-repressed P-TEFb to the HIV-1 and cellular target promoters. Nucleic Acids Research, 2014, 42, 4962-4971.	6.5	45

#	ARTICLE	IF	CITATIONS
19	On the way to find a cure: Purging latent HIV-1 reservoirs. <i>Biochemical Pharmacology</i> , 2017, 146, 10-22.	2.0	44
20	Genome-Wide Binding Map of the HIV-1 Tat Protein to the Human Genome. <i>PLoS ONE</i> , 2011, 6, e26894.	1.1	40
21	Protein Kinase C-Mediated Phosphorylation of BCL11B at Serine 2 Negatively Regulates Its Interaction with NuRD Complexes during CD4 <sup>+</sup> T-Cell Activation. <i>Molecular and Cellular Biology</i> , 2016, 36, 1881-1898.	1.1	27
22	The Many Lives of CTIP2: From AIDS to Cancer and Cardiac Hypertrophy. <i>Journal of Cellular Physiology</i> , 2014, 229, 533-537.	2.0	22
23	HIC1 controls cellular- and HIV-1- gene transcription via interactions with CTIP2 and HMGA1. <i>Scientific Reports</i> , 2016, 6, 34920.	1.6	22
24	HIV-1 Vpr mediates the depletion of the cellular repressor CTIP2 to counteract viral gene silencing. <i>Scientific Reports</i> , 2019, 9, 13154.	1.6	21
25	Human-Phosphate-Binding-Protein inhibits HIV-1 gene transcription and replication. <i>Virology Journal</i> , 2011, 8, 352.	1.4	18
26	Inhibition of HIV-1 gene transcription by KAP1 in myeloid lineage. <i>Scientific Reports</i> , 2021, 11, 2692.	1.6	17
27	Targeting the DNA-PK complex: Its rationale use in cancer and HIV-1 infection. <i>Biochemical Pharmacology</i> , 2019, 160, 80-91.	2.0	15
28	Improving combination antiretroviral therapy by targeting HIV-1 gene transcription. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 1311-1324.	1.5	13
29	Evolution of a concept: From accessory protein to key virulence factor, the case of HIV-1 Vpr. <i>Biochemical Pharmacology</i> , 2020, 180, 114128.	2.0	11
30	Novel role of UHRF1 in the epigenetic repression of the latent HIV-1. <i>EBioMedicine</i> , 2022, 79, 103985.	2.7	10
31	In Trauma Patients, the Occurrence of Early-Onset Nosocomial Infections is Associated With Increased Plasma Concentrations of Chromogranin A. <i>Shock</i> , 2018, 49, 522-528.	1.0	9
32	Analysis of RNA binding properties of human Ku protein reveals its interactions with 7SK snRNA and protein components of 7SK snRNP complex. <i>Biochimie</i> , 2020, 171-172, 110-123.	1.3	9
33	Suicide gene therapy in cancer and HIV-1 infection: An alternative to conventional treatments. <i>Biochemical Pharmacology</i> , 2022, 197, 114893.	2.0	8
34	Pseudomonas DING proteins as human transcriptional regulators and HIV-1 antagonists. <i>Virology Journal</i> , 2013, 10, 234.	1.4	7
35	Brain HIV-1 latently-infected reservoirs targeted by the suicide gene strategy. <i>Virology Journal</i> , 2021, 18, 107.	1.4	2
36	Flower power: Locking HIV in the gut with French lilac. <i>EBioMedicine</i> , 2021, 66, 103299.	2.7	1